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Abstract 
Porcine reproductive and respiratory syndrome (PRRS) is caused by PRRS virus (PRRSV), which infects primarily the 
respiratory tract of pigs. Thus intranasal (IN) delivery of a potent vaccine‑adjuvant formulation is promising. In this 
study, PRRS‑MLV (VR2332) was coadministered ± an adjuvant Mycobacterium vaccae whole cell lysate or CpG ODN 
through intramuscular (IM) or IN route as a mist, and challenged with a heterologous PRRSV 1‑4‑4 IN at 42 days 
post‑vaccination (dpv). At 14 and 26 dpv, vaccine viral RNA copies were one log greater in the plasma of PRRS‑MLV 
IM compared to IN vaccinated pigs, and the infectious replicating vaccine virus was detected only in the IM group. In 
PRRS‑MLV ± adjuvant IM vaccinated pigs, reduced viral RNA load and absence of the replicating challenged virus was 
observed at 7, 10 and 14 days post‑challenge (dpc). At 14 dpc, in BAL fluid ≥5 log viral RNA copies were detected in 
all the pig groups, but the replicating challenged virus was undetectable only in IM groups. Immunologically, virus 
neutralizing antibody titers in the plasma of IM (but not IN) vaccine groups was ≥8 against the vaccine and chal‑
lenged viruses. At 26 dpv, PRRS‑MLV IM (without adjuvant) received pigs had significantly increased population of 
CD4 and CD8 T cells in PBMC. At 14 dpc, relatively increased population of IFN‑γ+ total lymphocytes, NK, CD4, CD8 
and γδ T cells were observed in the MLV‑IM group. In conclusion, PRRS‑MLV IM vaccination induced the virus specific T 
cell response in pigs, but still it is required to improve its cross‑protective efficacy.
© 2016 Ouyang et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Porcine reproductive and respiratory syndrome (PRRS) is 
a respiratory disease of pigs of all ages and a reproduc-
tive disease of sows. PRRS is an endemic disease in the 
swine industry worldwide [1], and causes approximately 
$664 million losses annually in the USA [2]. PRRS virus 
(PRRSV) is the causative agent, isolated simultane-
ously in Europe and North America in the 1990s [3, 4]. 
PRRSV belongs to the Arteriviridae family [5] and dis-
plays a high genetic diversity [6]. To control PRRS, a 
modified live-attenuated PRRS vaccine (PRRS-MLV) has 
been widely used since the 1990s. PRRS-MLV protects 
pigs from clinical disease with reduced lung lesions [7] 
and viral shedding [8], and elicits a protective response 
against homologous virus. But apart from concerns 
about safety of PRRS-MLV in vaccinated pigs [9, 10], the 
breadth of cross-protection induced by MLV is highly 
questionable [11, 12].
Adjuvants are necessary to potentiate vaccine efficacy. 
Vaccine inoculated to a mucosal site along with a potent 
adjuvant upregulates the expression of costimulatory 
molecules on immune cells, which secrete chemokines 
and cytokines [13]. Mucosal vaccine coadministered 
through potent adjuvant/s induces superior cross-protec-
tive immunity by enhancing the array of antigen specific 
T and B cell responses; mediated by dramatic increase in 
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spreading of antigenic epitopes and recognition of multi-
ple conserved epitopes, which otherwise are not recog-
nized [14–17]. Thus, the potency of adjuvant and delivery 
system determine the degree of cross-protection. PRRSV 
causes disease primarily in the respiratory tract and thus 
intranasal (IN) delivery of PRRS-MLV with a potent 
adjuvant is promising.
We have demonstrated that pigs vaccinated with 
PRRS-MLV intranasally with a potent adjuvant, Myco-
bacterium tuberculosis whole cell lysate (M. tb WCL), 
elicits better cross-protective immune response against 
heterologous challenge than without adjuvant [16]. But 
large-scale production of M. tb WCL involves risk, time 
and cost, as M. tb is a Biosafety Level (BSL)-3 agent. 
Alternatively, a non-pathogenic Mycobacterium (M. vac-
cae) adjuvant was shown to stimulate cytotoxic T-cell 
response [18] and provides protective response against 
tuberculosis [19]. Another vaccine adjuvant, CpG-oligo-
deoxynucleotide (CpG-ODN), activates the professional 
antigen-presenting cells [20] and potentiates the anti-
body and cross-reactive T cell response in mice [21, 22] 
and pigs [23, 24].
Therefore, in this study we evaluated cross-protective 
efficacy of PRRS-MLV coadministered with adjuvant 
M. vaccae WCL or CpG ODN through the IM or IN 
route. Our results suggest that those two adjuvants are 
not potent enough to augment the breadth of immunity 
against PRRS; rather PRRS-MLV delivered IM without 
any adjuvant is relatively better. Our results suggest that 
further studies are required to improve the cross-pro-
tective efficacy of PRRS-MLV using other highly potent 
adjuvants delivered IM and IN.
Materials and methods
Cells, PRRSV and adjuvant
MARC-145 cells were used for growing PRRSV [25] and 
in immunological assays [26]. Cells were maintained in 
high glucose DMEM (HyClone, MA, USA) supplemented 
with 0.1 mM HEPES (Fisher Scientific, NJ, USA), antibi-
otic/antimycotic solution (HyClone, UT, USA) and 10% 
FBS (Atlanta Biologicals, GA, USA) at 37 °C in a humidi-
fied atmosphere with 5% CO2. DMEM containing 2% 
FBS was used to grow virus in MARC-145 cells. PRRS-
MLV was provided by Boehringer Ingelheim®. A field 
PRRSV strain 1-4-4 isolated from infected sows in Ohio 
was used to challenge pigs. PRRS-MLV parent strain 
VR2332 and a genetically variant Type 2 PRRSV strain 
MN184 [27] were used to analyze the virus specific neu-
tralizing antibody (NA) titers in plasma and BAL fluid 
samples.   PRRSV ORF5 nucleotide sequence similarity 
between vaccine strain VR2332 and challenge stain 1-4-4 
is 85.6%. All the PRRSV were propagated in MARC-145 
cells and aliquots were stored at −80 °C until use.
Mycobacterium vaccae (ATCC#23027) was grown in 
endotoxin free 7H9 medium at 37 °C in accordance with 
ATCC instructions, and the whole cell lysate (WCL) was 
prepared as previously described [28]. CpG ODN 2007 
(TCGTCGTTGTCGTTTTGTCGTT) in phosphoro-
thioate backbone was custom prepared (Integrated DNA 
Technologies, IA, USA). Five conserved T cell peptides 
of PRRSV, nsp10 (aa 2578-2628) CPGKNSFLDEAAYC-
NHL and (aa 2554-2604) VRILAGGWCPGKNSFLD; 
Nsp9 (aa 442-492) VRGNPERVKGVLQNTRF [29]; GP5 
(aa 445-489) KGRLYRWRSPVIIEK [30]; and N (aa 187-
213) VRHHFTPSE [31] were custom synthesized (Ther-
mofisher Scientific, NY, USA).
Pigs and inoculation
A total of 25 conventional Large White-Duroc crossbred 
4 week old pigs were procured from The Ohio State Uni-
versity swine herd, which were seronegative for PRRSV, 
porcine respiratory coronavirus, transmissible gastroen-
teritis virus and porcine circovirus 2. Pigs were allowed 
to acclimate for a week before initiation of the experi-
ment, and randomly divided into six groups (n = 4 or 5 
per group) (Figure  1A). Animals were maintained with 
Groups No. of pigs Vaccine Adjuvant Route
1 4 PBS No IM + IN
2 4 PRRS-MLV No IM
3 4 PRRS-MLV CpG ODN IM
4 4 PRRS-MLV CpG ODN IN
5 4 PRRS-MLV M. vaccae WCL IM
6 5 PRRS-MLV M. vaccae WCL IN
0 dpv 14 dpv 26 dpv 42 dpv
0 dpc
3 dpc 7 dpc 10 dpc 14 dpc
Vaccination
PRRSV challenge (strain 1-4-4) 
(5h105 TCID50/pig by IN route) Euthanize
A
B
Figure 1 PRRS-MLV vaccination and challenge study work 
plan. A Conventional crossbred pigs were randomly divided into six 
Groups (4 or 5 per Group). PRRS‑MLV was administered once without 
(saline) or with an adjuvant, M. vaccae WCL or CpG ODN, through 
intramuscular (IM) or intranasal (IN) route. B All the experimental pigs 
were challenged with a heterologous PRRSV strain 1‑4‑4 by IN route 
at 42 dpv. Blood samples were collected and rectal temperature and 
body weight were recorded at 0, 14, 26, 42 dpv and 3, 7, 10, 14 dpc 
and pigs were euthanized at 14 dpc.
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food and water ad libitum in our large animal BSL2 facil-
ity under the supervision of a veterinarian. The adjuvant 
(M. vaccae WCL 5 mg/pig or CPG-ODN 250 μg/pig) and 
PRRS-MLV (the same vaccine dose as per the manufac-
turer’s recommendation was inoculated either by IM or 
IN route) were not mixed for inoculation in pigs; and 
they were inoculated separately on either side of the 
neck through IM or IN to both nostrils as mist. The pig 
group vaccinated intranasally with PRRS-MLV with-
out adjuvant was not included in this study, but such a 
group was included in our previous study [16]. Each pig 
received 2  mL vaccine formulation once, with 1  mL of 
vaccine/adjuvant to each side of the neck or each nostril. 
Pigs were challenged using a heterologous PRRSV strain 
1-4-4 (5 × 105 TCID50 per pig) on 42 days post-vaccina-
tion (dpv) IN as mist and euthanized on 14  days post-
challenge (dpc) (Figure 1B). Rectal temperature and body 
weight of pigs were recorded during the experiment on 
the days of blood collection. Collection of samples, main-
tenance and euthanization of pigs were performed as per 
the approved animal use and care committee protocol of 
The Ohio state University.
Collection of blood samples and bronchoalveolar lavage 
fluid of pigs
For evaluation of viremia and PRRSV specific neutraliz-
ing antibody response, 5–7 mL of blood was collected at 
0, 14, 26, 42 dpv and 3, 7, 10, 14 dpc. Plasma was sepa-
rated using K2 EDTA plus blood collection tubes (BD 
vacutainer, NJ, USA) and preserved at −80 °C until use in 
the assays. At 26 dpv and 14 dpc, peripheral blood mono-
nuclear cells (PBMC) were isolated from blood collected 
in EDTA by gradient centrifugation using lymphoprep 
solution in sepmate tubes (Stem Cell Technologies, Can-
ada) [32]. PBMC were resuspended in enriched-RPMI 
(E-RPMI, RPMI containing 10  % FBS, 200  μm HEPES, 
1 mM sodium pyruvate, 25 μm 2-ME, 1× Non-Essential 
Amino Acid, and 1× antibiotic and antifungal). Bron-
choalveolar lavage (BAL) fluid was collected during 
necropsy as described previously [33] and aliquots were 
stored at −80 °C until use in the assays.
Virus and virus neutralizing antibody (NA) titration
Analysis of PRRSV and NA titers in plasma and BAL 
fluids were performed by indirect immunofluorescence 
assay (IFA) [34, 35]. Briefly, for virus titration confluent 
monolayer of MARC-145 cells in 96-well microtiter plate 
was treated with 10-fold dilution of samples for 48  h; 
for VNT, samples were heat (56  °C for 30 min) and UV 
(254 nm for 45 min) inactivated before use in the assay. 
Twofold serially diluted samples were incubated with 
equal volume of PRRSV (strain 1-4-4 and VR2332, 100 
TCID50 per well; strain MN184, 200 TCID50 per well) 
for 1  h at 37  °C, and the mixture was transferred into 
microtiter plates containing a confluent monolayer of 
MARC-145 cells and incubated for 48  h at 37  °C. Cell 
plates were fixed using acetone-Milli-Q water (8:2) mix-
ture for 10 min at room temperature (~20 °C) and dried. 
Plates were treated with anti-PRRSV nucleocapsid pro-
tein specific monoclonal antibody (SDOW17) (Rural 
Technologies Inc., SD, USA) (1:10 000) for 2 h at 37  °C, 
followed by Alexa Fluor 488 conjugated goat anti-mouse 
IgG (H + L) (Invitrogen, CA, USA) secondary antibody 
(1:4000). The plates were examined under a fluorescent 
microscope after mounting with glycerol-phosphate-
buffered saline (PBS) (6:4). The virus induced cytopathic 
effect was examined under a fluorescent microscope 
and the titer was calculated using the Reed and Muench 
method [34]. PRRSV titer was expressed as the 50% tis-
sue culture infective dose (TCID50) per mL. NA titer was 
the reciprocal dilution of the plasma or BAL fluid which 
caused >90% reduction in virus-specific fluorescence foci 
compared to virus control well.
Detection of PRRSV RNA load by qRT‑PCR
Plasma and BAL fluid samples were used in preparation 
of RNA by the MagMAX™ 96 viral RNA isolation kit 
(Ambion/Applied Biosystems, CA, USA) [33]. RNA isola-
tion was performed using 50 µL of sample using the Mag-
MAX™ Express Magnetic Particle Processor (Applied 
Biosystems, NY, USA) according to the manufacturer’s 
instructions. RNA was reverse transcribed into comple-
mentary DNA (cDNA) using Quantitect reverse tran-
scription kit (Qiagen, Germany). The cDNA was used in 
real-time PCR reaction with PerfeCta SYBR Green Fast 
Mix (Quanta Biosciences, MD, USA) using the PRRSV 
ORF6 gene derived forward primer (GATAACCACG 
CATTTGTCGTC) and reverse primer (TGCCGTT 
GTTATTTGGCATA). Standard curves were generated 
using serial dilution of known copies of the PCR product. 
PRRSV RNA copies in each mL of plasma and BAL fluid 
were determined.
Flow cytometric study of immune cell population
Flow cytometry analysis was performed to determine the 
population of lymphocyte subsets from 50 000 acquired 
events of immunostained PBMC [26, 33]. Briefly, PBMC 
isolated at 26 dpv and 14 dpc were plated (5 × 106 cells/
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well) in 48-well tissue culture plate in the presence of 
PRRSV strain 1-4-4 (5  ×  104 TCID50/well, 0.01 MOI) 
or pooled five PRRSV conserved peptides (1  μg/mL of 
each peptide) in 1 mL E-RPMI for 48 h at 37 °C with 5% 
CO2, and cells cultured with E-RPMI medium only were 
included as a control. GolgiStop protein transport inhibi-
tor (BD Bicoscience, CA, USA) and Goldiplug Brefeldin 
A (Sigma-aldrich, MO, USA) were added at the last 6 h 
of incubation [36, 37]. Cells were first surface-labeled 
using pig specific mAb (CD3ε, CD4α, CD8α, δ chain) 
conjugated with different fluorochromes [32, 38]. Sub-
sequently, cells were fixed, permeabilized and stained 
for intracellular IFN-γ using fluorochrome-conjugated 
mouse anti-pig IFN-γ mAb or its isotype control mAb 
(BD Biosciences, CA, USA). Immunostained cells were 
acquired using the BD Aria II flow cytometer and ana-
lyzed using the FlowJo software.
Ethics statement
This study was carried out in strict accordance with 
the recommendations by Public Health Service Policy, 
United States Department of Agriculture Regulations, 
the National Research Council’s Guide for the Care and 
Use of Laboratory Animals, and the Federation of Animal 
Science Societies’ Guide for the Care and Use of Agricul-
tural Animals in Agricultural Research and Teaching. All 
the relevant institutional, state and federal regulations 
and policies were followed regarding care and use of ani-
mals at the Ohio State.
Statistical analysis
All data were expressed as the mean value of 4 or 5 
pigs  ±  SEM. Statistical analyses were performed using 
the GraphPad Prism 6 software by applying one way 
ANOVA followed by the Tukey’s t-test. The statistical 
significance was considered at P < 0.05.
Results
Clinical outcome and PRRSV viral load in pigs
Although we did not observe any respiratory distress in 
the experimental pigs, Group 3 (MLV-CPG IM), Group 
4 (MLV-CPG IN) and Group 1 (PBS) pigs had moderate 
fever (>40  °C) at 7 and 10 dpc (Figure 2A). PRRSV titer 
(TCID50/mL) and RNA load (RNA copies/mL) in the 
plasma and BAL fluid were determined by qRT-PCR for 
PRRSV ORF6 and using MARC-145 cells for replicating 
infectious virus titers, respectively. In plasma, PRRSV 
RNA copies in Group 2 (MLV-IM), Group 3 (MLV-
CPG IM) and Group 5 (MLV-Vac IM) pigs were 1-2 log 
higher compared to Group 4 (MLV-CPG IN) and Group 
6 (MLV-Vac IN) at 14 and 26 dpv; and were 1-2 log lower 
at 7 and 10 dpc compared to Groups 4 and 6 (Figure 2B). 
In pre-challenged pigs, the replicating vaccine virus 
was detectable only in IM but not IN vaccinated groups 
(Figure 2C). At 7 dpc, detectable infectious virus in all the 
IM pig groups was absent and the data were statistically 
significant compared to pig Group 1 (PBS) (P < 0.01) and 
Group 4 (MLV-CPG IN) (P < 0.05) (Figure 2D). The rep-
licating virus was undetectable in the plasma of Group 4 
(MLV-CPG IN) at 14 dpc and at 10 and 14 dpc in Group 
6 pigs (Figure 2C).
In the BAL fluid, ≥5 log viral RNA copies were detected 
in all the pig Groups; in particular, all four pigs of Group 
1 (PBS) and Group 4 (MLV-CPG IN) had high levels of 
RNA copies (≥7 logs/mL) with 1-2 log greater than the 
other groups (Figure 2E). The replicating virus was absent 
in BAL fluid of all the IM pig groups, while one or two 
pigs in both the IN vaccinated groups still had infectious 
virus (Figure 2F).
Virus neutralizing antibody level in plasma and BAL fluid
PRRSV-specific NA titers in the plasma and BAL fluid 
against strains 1-4-4, VR2332 and MN184 were ana-
lyzed. In plasma, the NA titers against strains 1-4-4 and 
VR2332 were gradually increased in all the pig groups, 
and in IM vaccine groups the titers were two-fold higher 
than IN vaccine groups with mean titer ≥1:8 at 10 and 
14 dpc (Figures 3A and B). In contrast, NA titer against 
strain MN184 remained <1:8 in all the tested pig groups 
(Figure 3C). In BAL fluid, the NA titers against the three 
tested viral strains were <1:8 in most of the pig groups, 
and in Groups 5 and 6 against MN184 strain the NA 
titers were >1:8 (Figures 3D–F).
Phenotypic analysis of different T lymphocyte 
subpopulations in pigs
The population of CD3ε+CD4α−CD8α+ cells and 
T-helper/memory cells (CD3ε +CD4α+CD8α+) in PBMC 
of Group 2 (MLV-IM), Group 5 (MLV-Vac IM) and Group 
6 (MLV-Vac IN) pigs at 26 dpv was significantly increased 
compared to Group 1 (PBS) (Figures  4A  and B). Only 
MLV-Vac IM pig group had increased counts of γδ T cells 
compared to PBS control (Figure 4C). The population of 
CD3ε+CD4α−CD8α+ cells was significantly increased in 
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the MLV-Vac IN pig group restimulated with virus com-
pared to peptide stimulation at 14 dpc (Figure 4D).
At 26 dpv, none of the pig groups had increased acti-
vated (IFN-γ+) lymphocyte subsets (Figures  5A–C  and 
6A–C). But at 14 dpc, significantly increased pop-
ulation of total and CD3ε+ IFN-γ secreting cells 
and IFN-γ+ CD3ε−CD4α−CD8α+ (NK) cells were 
detected (Figures  5D–F). Also, IFN-γ positive CD3ε+ 
CD4α−CD8α+ (cytotoxic T cell (CTL)/γδ T cell), CD3ε+ 
CD4α+CD8α+ (T-helper/memory) and γδ T cells were 
observed in Group 2 (MLV-IM) pigs restimulated with 
the challenge virus ex vivo compared to control and other 
vaccine trial groups (Figures 6D–F). 
Discussion
The restriction fragment length polymorphism (RFLP) 
code for the Type 2 prototype PRRSV strain VR2332 
derived PRRS-MLV (Boehringer Ingelheim®) was 2-5-2 
[39], and it was passaged repeatedly in MARC-145 cells 
and became avirulent in pigs [32]. The RFLP code of the 
challenged field virus used in this study was 1-4-4, and it 
was widely prevalent in North America and has approxi-
mately 15% difference in amino acid sequence compared 
to VR2332 GP5 sequence [40]. Thus, we analyzed the 
efficacy of PRRS-MLV ± M. vaccae WCL or CPG ODN 
administered IM or IN against the genetically heterolo-
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Figure 2 Dynamics of body temperature and PRRSV load in the plasma and BAL fluid of pigs. (A) Rectal temperature of pigs was recorded 
at the indicated dpv and dpc. PRRSV RNA copies and replicating infectious virus load in the plasma (B–D) and BAL fluid (E, F) were quantified by 
qRT‑PCR and indirect immunofluorescence assay. The numbers above the bar in the graphs (E, F) represent the ratio of PRRSV positive pigs to the 
total in each group. Each data point or bar in the graph represents the average value from 4 or 5 pigs ± SEM. Asterisk marked in panel C indicates 
the virus titers in MLV‑IM, MLV‑CPG IM and MLV‑IM Groups were significantly reduced compared to mock (PBS) challenged Group (P < 0.01) and 
MLV‑CPG IN Group (P < 0.05) at 7 dpc. In panel D asterisks (*P < 0.05 and **P < 0.01) indicate statistical significant difference between the marked 
two pig Groups at 7 dpc.
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We previously demonstrated that pigs immunized 
with PRRS-MLV with M. tb WCL IN elicit cross-pro-
tective response against a heterologous PRRSV strain 
MN184, which also has 15% nucleotide difference in GP5 
sequence compared to VR2332 [16]. In this study, our 
results indicated that PRRS-MLV IM with and without 
adjuvant received pigs had 1-2 log reduced challenged 
viral RNA compared to IN route vaccinated animals. 
Further, in all the IM vaccinated pigs the replicating chal-
lenged virus was absent at 7, 10 and 14 dpc in plasma 
and also in BAL fluid at 14 dpc. Immunologically, these 
results were supported with NA titers of >1:8 against the 
strain 1-4-4 in IM vaccinated pigs. This data was con-
sistent with an earlier study wherein PRRSV NA titer 
of 1:8 or higher protects piglets against development of 
viremia [41, 42]. In this study, IM vaccinated pigs with 
a single dose of PRRS-MLV had partial protection to a 
heterologous challenge virus. Similar degree of partial 
protection was observed in a heterologous challenge 
study using a highly pathogenic PRRSV strain JX143 
derived PRRS-MLV vaccinated pigs [43].
The protective response against PRRSV in PRRS-MLV 
vaccinated pigs was found to be dependent more on the 
levels of cell-mediated than humoral immunity [44]. 
In pigs vaccinated intranasally using PRRS-MLV and 
a potent adjuvant, M. tb WCL substantially increased 
IFN-γ response associated with a greater than two-fold 
increase in the population of CD4 CD8 double positive 
T cells (T-helper/memory) in virus-challenged pigs [16]. 
In pigs vaccinated with an inactivated PRRSV delivered 
through a biodegradable nanoparticle, the frequency of 
IFN-γ+ CD4, CD8 and γδ T cell subsets were significantly 
enhanced and they were correlated well with the clear-





















































































































































































Figure 3 PRRSV neutralizing antibody (NA) titers in the plasma and BAL fluid of pigs. Viral NA titers in the plasma (A–C) and BAL fluid 
(D–F) against challenged PRRSV strain 1‑4‑4 (A, D), PRRS‑MLV parent strain VR2332 (B, E) and a genetically variant Type 2 PRRSV strain MN184 (C, 
F) were determined by indirect immunofluorescence assay. The NA titer of a sample was expressed as the reciprocal of the highest dilution that 
inhibited >90% of the virus induced immunofluorescence activity. Each data point or bar in the graph represents the average NA titer from 4 or 5 
pigs ± SEM.
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and lungs [33, 38]. This suggested a strong association of 
PRRSV clearance to IFN-γ+ T cell response, and there-
fore in this study we determined the population of vari-
ous IFN-γ positive T cell subsets. In pigs, the CD4 CD8 
double positive T cell was shown to possess memory 
and T helper phenotype, and upregulation of this acti-
vated T cell subset correlated strongly with the protective 
immune response against classical swine fever, Aujeszky’s 
disease and PRRSV [38, 45–47]. In PRRS-MLV (without 
adjuvant) IM received pigs, a significantly increased pop-
ulation of activated (IFN-γ+) CD4 CD8 double positive T 
cell was observed.
In addition, in pigs CD3ε+CD4α−CD8α+ bearing T 
cell is either a CTL or a γδ T cell, while the cell having 
the CD3ε+CD4α−CD8αβ+ phenotype is exclusively 
the CTL [48]. In PRRS-MLV IM (no adjuvant) vac-
cinated  pigs, enhanced population of a T cell bearing 
CD3ε+CD4α−CD8α+ phenotypic marker was detected 
at 26 dpv; and activated IFN-γ+ CD3ε+CD4α−CD8α+ 
and γδ T cells were detected in virus challenged pigs 
at 14 dpc. In addition, an upregulated IFN-γ+ NK cell 
population was observed. The recall activated lympho-
cyte response was detected using the challenged PRRSV, 
but not with pooled conserved five peptides of Type 
2 PRRSV of both structural and non-structural pro-
teins [29–31], suggesting that in our study tested pep-
tides may not be highly immunogenic in pigs. Overall, 
increased population of activated (IFN-γ+) T cell subsets 
A B C
D E F
Figure 4 Population of PRRSV specific lymphocyte subsets in the blood of pigs. PBMC isolated from individual pigs were unstimulated 
(control) or stimulated with PRRSV (virus) or pooled five conserved peptides (peptides) and immunostained using indicated pig specific cell surface 
markers and analyzed by flow cytometry. Population of CD3ε+CD4α−CD8α+, Th/memory cells (CD3ε+CD4α+CD8α+) and γδ T cells in the PBMC 
collected at 26 dpv (A–C) and 14 dpc (D–F) are shown. Each bar represents the average cell count of 50 000 events from 4 or 5 pigs ± SEM. Lower‑
case alphabets and asterisks indicate a statistically significant difference (a or *P < 0.05, b or **P < 0.01 and c P < 0.001) between control (PBS) and 
vaccine received pig groups under the same ex vivo stimulation condition, or between different stimulation conditions within the same treatment 
group.
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in PRRS-MLV IM received pig groups compared to IN 
delivery was observed. However, due to low NA titers in 
the IM vaccinated pigs, the T cell response data alone 
may not suggest the heightened heterologous protective 
response.
Both route of vaccination and administration of immu-
nomodulators must be considered in improving vaccine 
immunity [49]. Aase et  al. [50] report that IM immu-
nization with meningococcal outer membrane vesi-
cles in humans has induced significant IgG response, 
opsonophagocytic activity and serum bactericidal activity 
compared to IN group; but IN immunization with 10× 
more vaccine antigen induced persistent mucosal and 
systemic antibody responses with antibacterial activity. In 
conclusion, until we identify a cost-effective potent adju-
vant which has potent adjuvant effects akin to M. tb WCL, 
it is beneficial to use PRRS-MLV by IM route; which is 
currently practiced in most of the swine producing coun-




Figure 5 Population of PRRSV specific IFN-γ+ total lymphocyte response in the blood of pigs. PBMC isolated from individual pigs at 26 
dpv (A–C) and 14 dpc (D–F) were unstimulated (control) or stimulated with PRRSV strain 1‑4‑4 (virus) or pooled five conserved peptides (peptides). 
IFN‑γ secreting cells in total CD3ε+ lymphocytes and NK cells (CD3ε−CD4α−CD8α+) are shown. Each bar represents the average cell counts of 
50 000 events from 4 or 5 pigs ± SEM. Lowercase alphabet and asterisks indicate a statistically significant difference (a or *P < 0.05, **P < 0.01 and 
*** P < 0.001) between control (PBS) and vaccine received groups under the same ex vivo stimulation condition, or between different stimulation 
conditions within the same treatment group.
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